GREAT POINT PARTNERS LLC
Q3 2026 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001281446
· CRD 158423
· SEC-registered investment adviser
Consolidated report · includes
2 managers
since Q3 2013
$418.5M Reported Value Total
GREAT POINT PARTNERS, LLC reports 17 total accounts under management (AUM). There are 17 discretionary accounts valued at $1,777,101,406, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
38 funds
· $2.0B gross asset value
Private Equity Fund: $1.4B · Hedge Fund: $564.4M
Source: Form ADV filed 2026-03-31
Reported value
$418.5M
Quarter over quarter
-10.0%
Holdings
41
Top-10 concentration
49.5%
Filing Structure
Reports holdings for
- JAY JEFFREY R · File #028-12517 · since Q3 2013
- Nordahl Lillian (not a 13F filer in our records) · File #028-24470 · since Q3 2024
- Yehudai Ortav · File #028-20398 · Q3 2020 – Q2 2024
- KROIN DAVID (not a 13F filer in our records) · File #028-13262 · Q3 2013 – Q2 2020
Holdings reported by
- JAY JEFFREY R · Q2 2013 – Q2 2013 · declared by one filing
Key People
Form ADV owners & control persons
Jeffrey Robert Jay
ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR
Adam Brian Felsenthal
GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
Ronald Marc Panzier
CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $418.5M |
| Positions | 41 |
| Change in reported value | -20.9% |
| New positions | 9 |
| Exited positions | 5 |
| Position turnover | 30.4% |
| Top-10 concentration | 49.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
41 | $418.5M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
37 | $529.1M |
|
Q1 2026 13F
Filed May 15, 2026
|
39 | $435.1M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
29 | $308.4M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
28 | $242.5M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
26 | $153.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $188.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
26 | $212.2M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
29 | $339.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
33 | $522.0M |
|
Q1 2024 13F
Filed May 15, 2024
|
35 | $641.6M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
34 | $586.7M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
39 | $549.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
36 | $510.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
42 | $509.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
40 | $510.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
40 | $415.3M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
33 | $417.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
29 | $413.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
35 | $450.1M |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | IBRX P IMMUNITYBIO INC | $28.3M | 6.77% |
| 2 | VERA VERA THERAPEUTICS INC | $26.1M | 6.24% |
| 3 | VOR VOR BIOPHARMA INC | $21.5M | 5.14% |
| 4 | AMLX AMYLYX PHARMACEUTICALS INC | $20.4M | 4.87% |
| 5 | SGMT SAGIMET BIOSCIENCES INC | $19.4M | 4.63% |
| 6 | DFTX DEFINIUM THERAPEUTICS INC | $19.4M | 4.63% |
| 7 | IONS IONIS PHARMACEUTICALS INC | $18.8M | 4.48% |
| 8 | GMAB GENMAB A/S | $18.7M | 4.48% |
| 9 | SLGL SOL-GEL TECHNOLOGIES LTD | $17.8M | 4.25% |
| 10 | ZURA ZURA BIO LTD | $17.0M | 4.05% |
| 11 | LBRX LB PHARMACEUTICALS INC | $15.8M | 3.76% |
| 12 | ABVX ABIVAX SA | $15.3M | 3.67% |
| 13 | ANNX ANNEXON INC | $14.8M | 3.54% |
| 14 | BLTE BELITE BIO INC | $12.7M | 3.04% |
| 15 | EPRX EUPRAXIA PHARMACEUTICALS INC | $10.9M | 2.61% |
| 16 | NKTR NEKTAR THERAPEUTICS | $10.6M | 2.53% |
| 17 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $10.0M | 2.39% |
| 18 | ELYM CLIMB BIO INC | $9.2M | 2.19% |
| 19 | ABCL ABCELLERA BIOLOGICS INC | $8.8M | 2.09% |
| 20 | NGNE NEUROGENE INC | $8.3M | 1.99% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.